Bispecific Antibodies Market Review, Outlook, Future Analysis And Synthesis By 2026 Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a technologically advanced solution for dual targeting strategies within same molecule. Due to its dual specificity, bispecific antibody can aid in redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. Catumaxomab and blinatumomab are the two U.S. FDA approved bispecific antibody products, which would fuel growth of the bispecific antibodies market. Bispecific antibodies can be divided into three main classes namely, fragment, symmetric, and asymmetric antibodies. Fragment bispecific antibodies such as a nanobody DART and BiTE are currently undergoing clinical trials. Likewise, tetravalent BsAb - DVD and DAF symmetric antibodies are under research. Companies such as Sanofi S.A., Merck & Co., Inc. and Genentech, Inc. are conducting research on symmetric bispecific antibodies. BEAT, duobody, and crossmab are examples of asymmetric bispecific antibodies, which are currently being researched by Glenmark Pharmaceuticals, Eli Lilly and Company, and Genmab A/S. Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/19 Catumaxomab – The First Bispecific Antibody Boost Growth Of The Bispecific Antibodies Market: As of 2015, over 60 different BsAb formats have been developed, with some making their way into the clinical trials. Bispecific antibodies market growth is increasing due to the limitation of monoclonal antibodies in drug resistance and failure to respond in treatment. Hence, the bispecific antibodies market is projected to gain significant growth traction in the near future. Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat malignant ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was approved in Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand name Removab, Catumaxomab is administered to patients with EpCAM-poisitve carcinoma. North America and Europe are major regions for Bispecific antibodies market: In Europe and North America, incidence of diseases such as lung cancer, cervical cancer, breast cancer, and prostate cancer is increasing, with the regions accounting for the highest incidence rate for these diseases worldwide. Moreover, with these regions being home to major players, these are the largest bispecific antibodies market. Supportive government initiatives are further fueling growth of bispecific antibody treatment markets in North America and Europe. Increasing healthcare access and awareness in developing regions such as Asia Pacific, Latin America, and Middle East are projected to propel demand for BsAb owing to fuel growth of the bispecific antibodies market in the near future. Increasing Investments To Harness The Potential Of Highly Effective BsAb Drug Therapy: Various pharmaceutical companies are actively involved in development and manufacture of bispecific antibodies. MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in this field. Report includes chapters which deeply display the following deliverable about industry : • Bispecific Antibodies Market Research Objective and Assumption • Bispecific Antibodies Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Bispecific Antibodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Bispecific Antibodies Market, By Regions • Bispecific Antibodies Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Bispecific Antibodies Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Bispecific Antibodies Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Bispecific Antibodies Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key Players Involved In The Bispecific Antibodies Market Include: Some of the key players in Bispecific antibodies market are, • Amgen, Inc. • Bayer AG • Dow Pharmaceutical Solutions • ImmunGene, Inc. • Immunocore Limited • Merck & Co., Inc. • Novartis AG • Pfizer, Inc. • F. Hoffmann-La Roche AG Ask For Discount Before Purchase @ https://www.coherentmarketinsights.com/insight/request-discount/19 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen.
© Copyright 2024 Paperzz
